Skip to main content
. 2011 Jul 27;438(Pt 1):111–119. doi: 10.1042/BJ20101939

Figure 1. FPP activates PPARγ as shown by luciferase reporter assay.

Figure 1

(A) Schematic illustration of the mevalonate pathway. The targets of lovastatin and zaragozic acid are also shown. (BD) Effects of mevalonate metabolites (1 μM) or FPP on PPARγ or RXRα activity in a luciferase reporter assay using the GAL4/PPARγ chimaera system (B), full-length PPARγ system (C) or GAL4/PPARγ and GAL4/RXRα chimaera system (D). CV1 monkey kidney cells were transfected with pM-PPARγ, p4xUASg-tk-luc and pRL-CMV (B), pDEST-hPPARγ, p3xPPRE-tk-luc and pRL-CMV (C), or pM-PPARγ/pM-RXRα, p4xUASg-tk-luc and pRL-CMV (D). Cells were incubated in a medium with each mevalonate metabolite, Pio or LG100268 (LG; a synthetic RXR agonist) for another 24 h after the transfection. The activity of a vehicle control was set at 100% and the obtained relative luciferase activities are presented as the fold induction with respect to that in the vehicle control. All of the values are the means±S.E.M. for three or four tests.